TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers mapped immune aging using blood cells from 2,609 adults and found that a higher proportion of granzyme B-producing cells was associated with greater later risks of several chronic conditions and death. The findings are based on observational data, and the team is working on a simpler blood test; the map is not a diagnosis or a proven prediction tool for individual patients.
Researchers have created a map of immune aging that links the balance between two types of white blood cells to different long-term health outcomes. In a study published Oct. 9 in Immunity, a pattern dominated by granzyme B-producing cells was associated with higher risks of death and several chronic conditions in follow-up data, though the finding is not a diagnosis or proof that the cell pattern causes disease.
The team analyzed about 12.4 million immune cells from blood samples of 2,609 mainly healthy adults, ages 20 to over 90, across eight cohorts in North America, the United Kingdom, Asia and Australia. The researchers found that younger participants generally had more naive immune cells, which have not yet encountered specific pathogens. Older participants showed a wider range of immune profiles, including differences in cells linked with inflammation.
To describe those differences, researchers placed participants along a spectrum based on the ratio of granzyme B- and granzyme K-producing CD8 T cells. Granzyme B cells can directly destroy diseased cells. Granzyme K cells are less studied and may help signal for other immune cells, according to the report. The study then used blood-protein data from a smaller group with known CD8 T-cell counts to build a model for estimating where people fell on that spectrum.
The researchers applied the model to baseline blood-protein samples from 50,000 UK Biobank participants. That database follows health events for as long as 15 years. Participants whose estimated immune profiles leaned toward granzyme B were more likely to develop conditions including type 2 diabetes, hypertension, liver disease and renal failure, and had a higher risk of death a decade later than those with more granzyme K cells. The source does not provide absolute risk figures for these outcomes.
A Possible Signal Before Diagnosis
The work points to a possible way to identify differences in immune aging that are not captured by a person’s age in years. If future studies validate the pattern and a practical test can measure it reliably, clinicians could potentially use it to identify people who may need closer monitoring before a chronic condition is diagnosed.
That possibility remains a research goal, not an available screening recommendation. The observed associations do not establish that granzyme B cells cause the later illnesses, nor do they show that changing the cell balance would prevent them. The findings matter because they offer a candidate early-warning marker for further study, while underscoring the need to distinguish risk signals from individual predictions.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Map
The study combined two kinds of evidence. First, the researchers characterized immune cells in blood samples across several cohorts to describe how immune profiles varied with age. They then used a smaller dataset that included both CD8 T-cell counts and blood proteins to train a computer model. That step was needed because the UK Biobank data used for long-term follow-up did not include the CD8 T-cell counts required to place participants directly on the map.
The model estimated immune-spectrum positions from stored protein measurements in 50,000 UK Biobank participants, whose medical histories could then be examined over time. This design let the team compare the estimated baseline pattern with later health records, but it also means the long-term associations rely on modeled positions rather than direct CD8 T-cell counts for those 50,000 people.
Co-corresponding author Maxim N. Artyomov of Washington University School of Medicine said the blood may contain clues to whether someone is on a healthy or unhealthy aging trajectory. Coauthor Marina Terekhova cautioned that a higher granzyme B level in someone who appears healthy is not a formal disease diagnosis, but may indicate that the body is under stress.
“There are clues in the blood that can tell us whether someone is on a healthy or unhealthy aging trajectory.”
— Maxim N. Artyomov, co-corresponding author and professor at Washington University School of Medicine
As an affiliate, we earn on qualifying purchases.
Limits of the Risk Estimate
The findings show associations, not cause and effect. The report does not give absolute risk levels, explain how well the model predicts outcomes for an individual, or establish a threshold that clinicians could use to make decisions. It also does not show whether the same associations hold across all populations or for people with existing illness.
The UK Biobank analysis estimated immune-cell patterns from blood proteins because direct CD8 T-cell counts were unavailable in that dataset. Further research will need to test the model and any resulting blood test in independent groups, and determine how accurately it identifies risk. The study does not establish that a granzyme B-dominant profile can be reversed or that doing so changes disease outcomes.
blood test for chronic disease risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing a Simpler Blood Test
Artyomov and his lab are adapting the research toward a blood test using standard equipment, according to the report. The stated aim is a less costly way to assess immune aging than the specialized technology currently needed to position patients on the spectrum.
The report does not provide a development timeline, validation results for a clinical test, or plans for regulatory review. Before the approach could guide routine care, researchers would need to show that it produces reliable results, predicts outcomes beyond established risk factors and helps clinicians make decisions that improve health. For now, the map is a research finding rather than a screening test available to patients.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the immune aging study find?
Researchers reported that a granzyme B-dominant immune pattern was associated with higher later risks of death and several chronic conditions in an analysis using UK Biobank data. The study does not establish that the pattern causes those outcomes.
Does a high granzyme B level mean someone has a disease?
No. Study coauthor Marina Terekhova said the pattern is not a formal disease diagnosis. The researchers describe it as a possible sign of immune stress that requires further study.
How many people were included?
The team analyzed immune cells from 2,609 adults across eight cohorts. It also applied a model to blood-protein samples from 50,000 UK Biobank participants to examine associations with subsequent health records.
Can patients get this test now?
The report says the research team is working toward a simpler blood test, but it does not describe a validated test available for routine clinical use. The findings are not a basis for individual medical decisions.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
